bluuebunny/crossref_metadata_2025_split huggingface dataset:
Abstract 977: Combination treatment of pantoprazole and TRAIL reduce cell viability by activating caspase cascade and down-regulation of phosphorylated ERK in AGS cell line.
Authors: Roh Sang Young , Byun Jae Ho , Shim Byoungyong , Hong Young Seon 
Published: August 2014

Abstract
Background Pantoparzole(PPZ) is a proton pump inhibitor which is known to have an apoptotic activity in gastric cancer cells. Meanshile, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is known to induce apoptosis in cancer cells. However, some types of cancer cells, including AGS human gastric adenocarcinoma cells show resistance for the TRAIL-mediated apoptosis. This study was aimed to investigate the sensitizing effectcs of PPZ on TRAIL-mediated apoptosis in AGS cell line.
Methods Sensitivity to TRAIL and activation of TRAIL-induced apoptotic pathways were analyzed in AGS cell lines. WST-1 method was used to evaluate cell viability; Western blots was used to evaluate TRAIL-induced apoptosis.
Results TRAIL alone had little effect on apoptosis in AGS cells. However, treatment with TRAIL in combination with subtoxic concentrations of PPZ sensitized TRAIL-mediated apoptosis in AGS cells. Combined treatment of PPZ and TRAIL induced caspase(caspase-8, -9, -3) and the pro-apoptotic molecules (Bax). In addition, the down regulation of phosphorylated ERK were also found in cells treated with the combination of PPZ and TRAIL.
Conclusion The combination of TRAIL and PPZ may be considered as an approach to overcome the resistance of TRAIL in cancer treatment.
Citation Format: Sang Young Roh, Jae Ho Byun, Byoungyong Shim, Young Seon Hong. Combination treatment of pantoprazole and TRAIL reduce cell viability by activating caspase cascade and down-regulation of phosphorylated ERK in AGS cell line. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 977. doi:10.1158/1538-7445.AM2013-977
Abstract 98: The biological significance of T3-regulated endoglin in human hepatoma cells.
Authors: Lin Yang-Hsiang , Huang Ya-Hui , Chung I-Hsiao , Lin Kwang-Huei 
Published: August 2014

Abstract
Hypothyroidism has been associated with significantly elevated risk for hepatocellular carcinoma (HCC), although the precise underlying mechanisms remain unknown at present. Thyroid hormone (T3) and its receptor (TR) are involved in metabolism and growth. Endoglin is a T3/TR candidate target gene identified from our previous studies. Here, we demonstrated that T3 positively regulates endoglin mRNA and protein levels, both in vitro and in vivo. The thyroid hormone response elements (TRE) of endoglin were identified at positions -2114/-2004 and -2032/-1973 of the promoter region using the electrophoretic mobility shift assay (EMSA) and chromatin immunoprecipitation (ChIP) assay. Endoglin was downregulated in subgroups of HCC patients, and significantly associated with histology grade (negative association, p = 0.001), and this expression level was significantly associated with TRα1 in these HCC patients. Knockdown of endoglin expression in HCC cells promoted cell proliferation in the presence of T3. Moreover, endoglin stabilized p21 expression at the translational level. Based on the collective findings, we propose that endoglin is stimulated by T3 to stabilize p21, leading to the inhibition of cell proliferation. Endoglin and TRα1 levels are reduced in HCC, resulting in increased proliferative activity.
Citation Format: Yang-Hsiang Lin, Ya-Hui Huang, I-Hsiao Chung, Kwang-Huei Lin. The biological significance of T3-regulated endoglin in human hepatoma cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 98. doi:10.1158/1538-7445.AM2013-98
Abstract 981: The role of caffeine in sensitizing lung cancer cells to cisplatin-induced apoptosis.
Authors: Wang Gan 
Published: August 2014

Abstract
Cisplatin is an important anticancer drug that has been used widely for treatment of many types of cancer, including lung cancer. The effectiveness of the drug, however, often diminishes quickly due to the development of tumor cell drug resistance in patients. Therefore, it is important to explore different strategies that either can sensitize tumor cells to cisplatin or can reverse the tumor cell drug resistance. We have studies the effect of caffeine in cisplatin-induced apoptosis of lung cancer cells. Using both CRL5985 lung adenocarcinoma cells and HTB182 lung squamous carcinoma cells, the results of our caspase-3 activation studies demonstrated that the caffeine prior treatment significantly increased the cisplatin-induced caspase-3 activation in these lung cancer cells. Our quantitative PCR (real time PCR) results revealed that the prior caffeine treatment caused a great increase in transcription of PUMA, a pro-apoptotic protein, in the cisplatin-treated HTB182 and CRL5985 lung cancer cells. Our western blot results further indicated that the protein level of the PUMA was significantly more increased when the lung cancer cells was treated with caffeine prior to the cisplatin treatment. In addition, our western blot results also revealed that the phosphorylation level of Chk1 at serine 317 was decreased but the phosphorylation level of ATM at serine 1981 was increased for the lung cancer cells treated with caffeine prior to the cisplatin treatment compared to that of the cells treated with only cisplatin. These results suggest that caffeine can sensitize lung cancer cells to cisplatin via inhibiting ATR but increasing ATM activation, resulting in an increase in PUMA expression and apoptosis of the treated lung cancer cells. Therefore, caffeine can sensitize lung cancer cells to cisplatin-induced apoptosis.
Citation Format: Gan Wang. The role of caffeine in sensitizing lung cancer cells to cisplatin-induced apoptosis. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 981. doi:10.1158/1538-7445.AM2013-981
Abstract 987: XCE853: A novel anticancer candidate preferentially killing drug-resistant human tumor cells.
Authors: Gutmann Matthieu , Briand Jean-François , Prevost Gregoire Pierre , Carniato Denis , Pitty Marc-Henry 
Published: August 2014

Abstract
Cancer drug pan-resistance is associated with patients having a disease progression despite receiving new treatments. Often resistance arises in two steps, initially, the tumor responds to the drug, but not all tumor cells are killed leading to a selection of tumor cells that do not respond to any current drug. The nature of the residual disease is linked to different conditions such the efflux pumps, the quiescent cells, the stem cells, the DNA repair deficiency or the EMT. Here, we have identified a family of synthetic compounds displaying a preferential antiproliferative activity on drug resistant human cancer cells. The lead compound XCE853 is 5 to 94 more potent on drug resistant cancer cell lines compared to their parental tumor cell lines (HL60/HL60-Doxorubicin; MCF7/MCF7-Doxorubicin; A2780/A2780-Cisplatin and A549/AA549-Taxotere). XCE853 induced a strong and irreversible cytolysis of MCF7-Adriamycin cells after a short exposure in vitro (250nM, 6 hours). The mechanism of action of XCE853 is independent of efflux pumps and involves an early high ROS production leading to cell death by autophagy. The antitumor activity of XCE853 is also observed using in vivo xenograft models of human NSCLC. Altogether, these data support further efforts on this drug candidate to better understand its molecular mechanism of action and the description of the most sensitive tumor types.
Citation Format: Matthieu Gutmann, Jean-François Briand, Gregoire Pierre Prevost, Denis Carniato, Marc-Henry Pitty. XCE853: A novel anticancer candidate preferentially killing drug-resistant human tumor cells. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr 987. doi:10.1158/1538-7445.AM2013-987
Abstract ADV01: National Cervical Cancer Coalition.
Authors: Appel-Prigo Michele 
Published: August 2014

Abstract
The National Cervical Cancer Coalition (NCCC) was founded in 1996 as a grass-roots non-profit dedicated to serving women with, or at risk for, cervical cancer and HPV disease. In 2011 the NCCC merged with the American Social Health Association (ASHA). Since the early 1900s, ASHA has been educating and raising awareness on sexual health issues.
The NCCC coordinates outreach efforts with healthcare providers, bio tech firms, cancer researchers, and hospitals. These efforts include low and no-cost screening programs, vaccination information, psychological support to women, family members, friends, and caregivers to those currently seeking treatment, survivors, and those who have lost loved ones.
Citation Format: Michele Appel-Prigo. National Cervical Cancer Coalition. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr ADV01. doi:10.1158/1538-7445.AM2013-ADV01
Abstract ADV03: My breast cancer yellow brick road.
Authors: Axler Susan 
Published: August 2014

Abstract
From DCIS, stage 0 breast cancer, to invasive recurrence four years later, to Stage IV spread eight years after that, and now living with advanced breast cancer since 2000, I have traveled the winding path of researching, support groups, consultations, treatment and therapies. My road is not one solid concrete walkway. One organization cannot do it all: research innovative technologies and signaling cellular pathology; provide funding for research grants; support patients and families; meet financial needs as they arise. I started on this winding road when I questioned my route and I tiptoed gingerly at first, then raced along, often stumbling, to physicians and organizations that could make a difference and help me with my decisions.
ACS's Reach to Recovery mission "…dedicated to eliminating cancer…by preventing cancer, saving lives, and diminishing suffering from cancer, through research, education, advocacy and service" and "to assist people with breast cancer throughout the continuum of their disease experience." Linda Creed Foundation, working hand and hand with the National Breast Cancer Coalition whose mission has become curing breast cancer by 2020, lobbies full force making yellow bricks stronger, funding major innovative and costly research, for consumer-advocate input on review panels for grants from Department of Defense.
Metastic Breast Cancer Network's mission "to raise awareness of metastatic breast cancer by putting a public face on the metastatic experience (and) give those living with Stage IV disease a greater voice and visibility in the breast cancer and research communities as well as the public at large," provides education and information on treatments and coping. My road includes other organizations that lovingly mold beautiful yellow bricks. The Cancer Support Community (formerly Gilda's Club and the Wellness Community) provides educational and emotional resources. The S.J. Cancer Fund's patient assistance mission addresses financial needs such as paying utility bills, transportation and medical co-pay bills, and Living Beyond Breast Cancer does anything and everything they can to help the breast cancer patient, from phone support for first timers or recurrent "survivors," to conferences, to special events providing companionship and letting women know they are not alone.
Citation Format: Susan Axler. My breast cancer yellow brick road. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr ADV03. doi:10.1158/1538-7445.AM2013-ADV03
Abstract ADV05: From the golf course to education, outreach, and support for prostate cancer.
Authors: Brown Egbert 
Published: August 2014

Abstract
Central Ohio Men Against Prostate Cancer (COMAPC) is a community-based, all volunteer, non-profit organization. Our mission is to increase prostate cancer awareness and routine screening through education, support, and advocacy across cultural and economic barriers. Our primary focus is to reduce disparities that exist in prostate cancer among minorities and the medically underserved.
Prostate cancer is the second leading cause of cancer death in African American men. An estimated 35,110 cases of prostate cancer were expected to occur among African American men in 2011, accounting for 40% of all cancers diagnosed in African American men. It was estimated that 5,300 deaths from prostate cancer would occur in African American men in 2011. In addition, African American men have the highest mortality rate for prostate cancer of any racial or ethnic group in the United States with the death rate being 1 in 22 cases compared to 1 in 38 cases for white men.
Our goal is to help Central Ohio men and their families become more informed about prostate cancer, better informed about treatment options for the disease and encourage men to seek early screening. COMAPC provides prostate cancer education, outreach and support for men, the friends and families of at-risk men and those diagnosed with prostate cancer. Our efforts help people connect with those resources so they become more aware of prostate cancer, better informed about treatment options, and support men to seek early screening for prostate cancer.
Individual COMAPC board members actively participate in national service and advocacy initiatives such as the U. S. Army Research and Materials Command Prostate Cancer Research Program. American Association of Cancer Research Survivor&lt;-&gt;Advocate Program, US Too National Prostate Cancer Education and Support Team, National Association of African American Prostate Cancer Advocates, National Alliance of State Prostate Cancer Coalitions, American Cancer Society Cancer Action Network, We Work for Health-Ohio, and State and National Congressional Lobby Days.
Citation Format: Egbert Brown. From the golf course to education, outreach, and support for prostate cancer. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr ADV05. doi:10.1158/1538-7445.AM2013-ADV05
Abstract ADV11: Cancer communication to minority populations/MOCHA Prostate Cancer Symposium.
Authors: Jeames Sanford E. 
Published: August 2014

Abstract
The development of programs targeted toward underrepresented populations and evaluation of communications strategies to assess the effectiveness of such programs to improve health outcomes is essential to diminish disparities. The purpose of this research is to evaluate the effectiveness of a community symposium and education program to highlight prostate cancer disparities among high risk populations.
MOCHA was contacted in March 2012, by Mass Department of Public Health, to present a community program to highlight prostate cancer. The prostate cancer symposium was intended to utilize an innovative community based partnership and research concept to disseminate health information in specific settings for special populations. Over 150 persons attended the MOCHA Prostate Cancer symposium, held at a regional convention and events center in Springfield, Massachusetts. 118 completed distributed surveys to assess opinions about PSA screening and impact of program format.
A utilization of community based programs that focus on minority populations can represent an effective strategy and approach to communicate with special populations- particularly men of color. Men of color still support use of PSA blood test as a screening tool for prostate cancer, and minority groups will attend symposiums if encouraged by representatives that resemble their population. Men of color will support programs with research focuses and find information beneficial to their overall health.
Citation Format: Sanford E. Jeames. Cancer communication to minority populations/MOCHA Prostate Cancer Symposium. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr ADV11. doi:10.1158/1538-7445.AM2013-ADV11
Abstract ADV17: A journey from diagnosis to survivor to advocate.
Authors: Parks Meredith 
Published: August 2014

Abstract
In September 2011, at age 43, Meredith Parks was diagnosed with triple negative breast cancer. She had no medical history and was a mother of four young, school-age children. With the tireless support of her husband, Michael, and other family members, Meredith beat the disease.
In the 16 months since her diagnosis, Meredith has had six rounds of chemotherapy, five surgeries, including a bilateral mastectomy and participated in a clinical trial for 12 months. While undergoing chemotherapy, Meredith captained and organized a team of 82 Relay for Life “Team Meredith” members, who walked 18 hours in June and contributed over $12,000 to Cancer Research. In addition to participating in the AACR Scientist&lt;-&gt;Survivor Program, Meredith is a Komen Advocate in Science. Meredith is also an active volunteer in the Johns Hopkins Breast Center in Baltimore, MD, where she provides one-on-one support in their imaging center.
Meredith has found the answer to the question, “Why am I here?” She is determined to assist those furthering the hope, drive and necessity of a cure.
Citation Format: Meredith Parks. A journey from diagnosis to survivor to advocate. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr ADV17. doi:10.1158/1538-7445.AM2013-ADV17
Abstract ADV19: A mayo clinic cancer center spore-wide approach to advocacy.
Authors: Rieder Mark 
Published: August 2014

Abstract
The Mayo Clinica Inter-SPORE Advocates Group is to help all of the patient advocates at mayo become more educated and qualified.
Our mission statement is: Support and improve each disease-specific SPORE advocace group through sharing ideas, information and experiences.
The goals of the Mayo Clinic Inter-SPORE Advocates Group are:
- promote a collaborative relationship among the disease specific SPORE advocate groups in support of SPORE research, education and activities
- explore opportunities for collaboration on activities
- support a collaborative relationship across the SPOREs to further the translational research goals of each SPORE
- promote communications, education, and awareness among researchers, advcoates and patients
- participate in development of research proposals and informed consent for SPORE projects and clinical studies
The Mayo Clinic Inter-SPORE Advocates Group meets quarterly to share ideas information and experiences in its pursuit of a collaboratie relationship among the disease-specific SPORE advocate groups. Conference call-in is provided for those who cannot attend in person. The Group will continually assiss its efforts and look for opportunities to add value to the SPORE advocate groups.
Citation Format: Mark Rieder. A mayo clinic cancer center spore-wide approach to advocacy. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr ADV19. doi:10.1158/1538-7445.AM2013-ADV19
Abstract ADV24: Clinical Trials may be the safer treatment option with Personalized Medicine.
Authors: Whelan Jack 
Published: August 2014

Abstract
The next generation of scientists and investigators that embrace the latest generation of Health IT, will play a pivotal role in developing solutions that deliver on the promise of Personalized Medicine. The poster presented shows Jack Whelan's six year journey and five clinical trials/treatment options for his rare, incurable blood cancer, his e-Patient observations about Clinical Trials and Personalized Medicine and recommended sources of patient advocate educational materials for these subject matters.
Citation Format: Jack Whelan. Clinical Trials may be the safer treatment option with Personalized Medicine. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr ADV24. doi:10.1158/1538-7445.AM2013-ADV24
Abstract ADV25: Relentless in the fight against blood cancer: The Leukemia & Lymphoma Society.
Authors: Wilkerson Lauren 
Published: August 2014

Abstract
Founded in 1949, The Leukemia & Lymphoma Society (LLS) is the world's largest voluntary health organization desiccated to funding blood cancer research and providing education and patient services.
Our Mission: cure leukemia, lymphoma, Hodgkin's disease and myeloma and improve the quality of life for patients and their families.
What we do: Invest in blood cancer research. Provide critical information and support for patients and their families. LLS's innovative programs and services are reviewed by nationally recognized thought leaders in hematology and oncology, helping us provide the best services to our patients. Advocate for issues impacting blood cancers.
Why: An estimated 1.1 million people in the United States are living with, or are in remission from leukemia, Hodgkin lymphoma, non-Hodgkin lymphoma or myeloma.
Who we serve: In additional to our national headquarters in White Plains, NY, we have a network of 61 chapters throughout the United States and Canada. Our constituents live in urban, suburban and rural communities, seek treatments and large comprehensive cancer centers and community clinics and represent cultures from around the world. We work in partnership with community organizations, treatments centers and government agencies to deliver quality cancer support services to patients in our region. We work in partnership with other oncology and health organizations to meet the needs of underserved people within our community.
Citation Format: Lauren Wilkerson. Relentless in the fight against blood cancer: The Leukemia & Lymphoma Society. [abstract]. In: Proceedings of the 104th Annual Meeting of the American Association for Cancer Research; 2013 Apr 6-10; Washington, DC. Philadelphia (PA): AACR; Cancer Res 2013;73(8 Suppl):Abstract nr ADV25. doi:10.1158/1538-7445.AM2013-ADV25